Molecular pathology and molecular pharmacology of osteosarcoma

M. Ladanyi, R. Gorlick

Research output: Contribution to journalArticlepeer-review

26 Scopus citations


Abnormalities of many tumor suppressor genes and oncogenes have been described in osteosarcoma, but separating early or primary from secondary or late genetic lesions has been difficult. Among early lesions, inactivation of both the P53 and RB pathways appears to be a central and perhaps necessary event in osteosarcomagenesis. We propose a working model for the molecular pathology of osteosarcoma and we review the numerous published studies examining the association of various molecular features with either advanced presentation, poor chemotherapy response or decreased patient survival.

Original languageEnglish (US)
Pages (from-to)391-413
Number of pages23
JournalPediatric Pathology and Molecular Medicine
Issue number5
StatePublished - 2000
Externally publishedYes


  • Cyclin dependent kinase (CDK)
  • Retinoblastoma (RB)

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pathology and Forensic Medicine


Dive into the research topics of 'Molecular pathology and molecular pharmacology of osteosarcoma'. Together they form a unique fingerprint.

Cite this